Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

A Fierce Pharma Marketing review of the LinkedIn and Instagram pages of the 20 largest pharmas found that, as of Thursday, ...

The government issued a serious warning relating to sexual health for Mounjaro users. And tomorrow (23 June), the weight loss ...

I've been writing this column, I've devoted millions of words to east Arkansas. Having spent four years working for the Delta ...

Hims & Hers stock drops after Wegovy manufacturer ends deal to distribute weight loss drug - Hims & Hers had partnered with ...

On June 20, the Global Connectivity Industrial Interaction International Sports Industry Salon was held in Hong Kong. The event was hosted by National Business Daily, organized by NBD Think Tank Hong ...

Eli Lilly faces market headwinds, slowing growth, and rising competition. Discover why now might be the time for LLY ...

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

Baron Funds, an investment management company, released its “Baron Fifth Avenue Growth Fund” first quarter 2025 investor ...